CN116716345A - Method for preparing humanized RHO and or RHO mutant mice and application thereof - Google Patents

Abstract

The invention belongs to the fields of animal genetic engineering and genetic modification, and particularly discloses a method for preparing humanized RHO and or RHO mutant mice and application thereof; the method comprises replacing a mouse RHO nucleic acid sequence with a human RHO nucleic acid sequence or a mutant sequence thereof to form a modified RHO gene encoding a human or humanized RHO protein. The invention adopts homologous recombination technology to replace the full length of the Rho gene of the mouse with the full length of the RHO gene of the human or the mutant gene thereof, realizes one-step targeting in ES cells, and the obtained mouse has reproductive transmission capability and short period; the mouse does not express the mouse Rho endogenous gene any more, and drives the transcription regulation of the human Rho full-length sequence under the endogenous regulation element of the mouse, so that various sequences in treatment evaluation can completely target the human Rho sequence, and the method has good application prospect in developing medicaments for treating diseases related to the Rho gene mutation.

Description

Method for preparing humanized RHO and or RHO mutant mice and application thereof

Technical Field

The invention belongs to the fields of animal genetic engineering and genetic modification, and particularly discloses a method for preparing humanized RHO and/or RHO mutant mice and application thereof.

Background

Rhodopsin protein encoded by the RHO gene is mainly expressed in the extracellular node of rods, and is important for optical signal transduction. Most RHO mutations result in high expression levels of rhodopsin in photoreceptor cells, so that a large number of mutant protein cells are abnormally positioned, aggregated and severely degraded in protein, so that photoreceptor cells die and cannot perform normal optical signal transduction function. RHO mutant RP patients developed first symptoms more than 20 years old.

Current research on RHO gene mutation considers that the pathogenic mechanism is mainly gain of function, including influencing: (1) Rhodopsin protein folds, causing endoplasmic reticulum pressure and protein aggregate formation; (2) 11-cis-retinal binding, G protein coupling activation, binding and endocytosis of rhodopsin inhibitory proteins; (3) Cell trafficking of rhodopsin, including trafficking after golgi, targeting outer segment membrane, and the like.

Currently, over 150 RHO gene mutations have been identified as being associated with dominant RP, with missense mutations being dominant. P23H is the first RHO gene mutation found, accounting for about 12% of patients in the United states, but rarely found in patients in other countries. Mutation of the RHO gene of P23H results in incorrect folding of the protein, resulting in endoplasmic reticulum stress and cytotoxicity, and eventually in rod cell degeneration.

RHO mutations fall into two categories: class a mutations result in early loss of night vision and rod dysfunction throughout the retina; class B mutations result in slower disease progression, with the patient retaining normal rod photoreceptor cells to adulthood, at least in some parts of the retina.

Patients with class B mutations are more suitable for gene therapy due to the prolonged viability of the affected cells. For dominant diseases, treatment may require suppression of mutant alleles to avoid their suppression; or by gene correction, gene editing is used to achieve both gene amplification and mutation suppression. Almost all characterized RHO mutants are dominant and therefore may require silencing of the mutant allele to prevent blindness, while at the same time increasing normal gene expression for better treatment of the disease.

The use of animal models helps to drive the further transformation of RHO-related potential therapeutic approaches into clinical trials, as currently, there are siRNA, ASO, CRISPR, etc. gene therapies targeting the RHO gene to treat RP.

Assessment of specific targeting of human RHO and/or RHO-P23H is performed as usual in non-human animals such as rodents, e.g. mice or rats. However, such sequences cannot be properly determined in certain non-human animals because they do not target endogenous RHO and/or RHO-P23H proteins.

Accordingly, there is a need for a non-human animal, such as a rodent, e.g., a murine, e.g., a mouse or rat, wherein the non-human animal's RHO and/or RHO-P23H genes are wholly or partially humanized or replaced (e.g., at an endogenous non-human locus) with human RHO and/or RHO-P23H genes comprising sequences encoding human or humanized RHO and/or RHO-P23H proteins, respectively.

There is also a need for a non-human animal comprising the RHO and/or RHO-P23H gene (e.g. humanized or human) in which the RHO and/or RHO-P23H gene is under the control of a non-human regulatory element (e.g. endogenous regulatory element).

There is also a need for a humanized non-human animal that expresses human or humanized RHO proteins in the eye that are expressed such that the eye phenotype of an age-matched non-human animal is normal, and that expresses functional RHO proteins, and that expresses human or humanized RHO-P23H proteins in the eye that are expressed such that the eye phenotype of an age-matched non-human animal is abnormal.

Disclosure of Invention

To address the above problems, disclosed herein are non-human animals comprising a nucleic acid sequence encoding a RHO and/or RHO-P23H protein comprising a human gene sequence, transgenic non-human animals comprising a human RHO and/or RHO-P23H gene in whole or in part, and non-human animals expressing human or humanized RHO and/or RHO-P23H proteins, and, in addition, methods for making and using non-human animals comprising a human or humanized RHO and/or RHO-P23H nucleic acid sequence.

In order to achieve the above purpose, the invention adopts the following technical scheme:

a method for preparing a humanized RHO and or a RHO mutant mouse, the method comprising replacing a mouse RHO nucleic acid sequence with a human RHO nucleic acid sequence or a mutant sequence thereof to form a modified RHO gene encoding a human or humanized RHO protein.

Further, a method for preparing a humanized RHO and/or RHO mutant mouse is described above, wherein the RHO mutant is RHO-P23H.

Further, a method for preparing a humanized RHO and/or RHO mutant mouse as described above comprises the steps of: the mouse full-length RHO locus was replaced with 7.1kb human RHO genomic sequence and or with a 7.1kb fragment of the corresponding human RHO-P23H genomic DNA.

Further, a method for preparing a humanized RHO and/or RHO mutant mouse, said mouse being a C57BL/6J mouse, said method comprising the steps of:

1) Constructing a targeting vector containing a human RHO or RHO-P23H sequence;

2) Transferring the targeting vector into mouse ES cells for homologous recombination to obtain positive ES cells;

3) Positive ES cell blastula injection to obtain F0 mice;

4) Identifying the genotype of the F0 mouse;

5) Producing F1 mice;

6) Producing F2 mice;

7) Phenotypic analysis of F2 mice.

Further, a method for preparing a humanized RHO and/or RHO mutant mouse as described above, wherein the targeting vector in step 1) comprises:

a 5 'homology arm sequence, a human RHO genomic sequence, an antibody screening element, and a 3' homology arm;

wherein the homologous arm sequence is amplified from the genome of a C57BL/6J mouse, and the human RHO genome sequence is cloned from BAC: RP11-90I 14.

Further, a method for preparing a humanized RHO and/or RHO mutant mouse as described above, the homologous recombination of step 2) comprises the steps of:

and (3) electrically transferring the constructed targeting vector into ES cells of a C57BL/6J strain, screening the ES clones with drug resistance through drug screening, culturing and amplifying the related ES clones, and then carrying out PCR typing identification and Southern identification to obtain positive ES cells with correct targeting.

Further, a method for preparing a humanized RHO and/or RHO mutant mouse as described above, the preparation method comprising the steps of:

(1) Constructing a targeting vector, wherein the targeting vector comprises a 5 'homology arm sequence, a human RHO genome sequence, an antibody screening element and a 3' homology arm, wherein the homology arm sequence is obtained by amplifying a genome of a C57BL/6J mouse, and the human RHO genome sequence is obtained by cloning BAC: RP11-90I 14;

(2) Electrotransferring the constructed plasmid into ES cells of a C57BL/6J strain, screening medicines, selecting the ES clone with medicine resistance, culturing and amplifying the related ES clone, and carrying out PCR typing identification and Southern identification to obtain positive ES cells with correct targeting;

(3) Injecting positive ES cells into blastula, transplanting blastula into a surrogate mice, and birth of the mice after about 20 days of gestation;

(4) Shearing young mouse paws of 5-7d, extracting DNA, and carrying out PCR typing identification to confirm the genotype of the mouse;

(5) After male foundation mice are mated with wild-type heterologous mice for 8 weeks of age to obtain F1 generation heterozygote mice, carrying out PCR identification on the mice after 7 days of birth, and if positive mice are born, indicating that transgenes are integrated into germ cells;

(6) After male F1 mice reach 8 weeks of age, female F1 mice reach 6 weeks of age, carrying out mutual hybridization, and carrying out PCR identification after F2 mice are born for 7 days, and confirming the birth of homozygote mice;

(7) Phenotype analysis is carried out on RHO homozygote mice and RHO-P23H heterozygote mice, and other characteristics such as retina morphology, structure and the like are analyzed.

Further, a method for preparing a humanized RHO and/or RHO mutant mouse as described above,

the 5' homologous arm sequence is shown as SEQ ID NO. 1;

the 3' homologous arm sequence is shown as SEQ ID NO. 7;

the human RHO genome sequence is shown as SEQ ID NO. 4.

Further, a method for preparing a humanized RHO and/or RHO mutant mouse as described above,

the upstream and downstream primer sequences for obtaining the 5' homologous arm sequences are respectively shown as SEQ ID NO. 2 and SEQ ID NO. 3;

the upstream and downstream primer sequences for obtaining the 3' homologous arm sequences are respectively shown as SEQ ID NO. 8 and SEQ ID NO. 9;

the sequences of the upstream and downstream primers for obtaining the human RHO genome sequence are respectively shown as SEQ ID NO. 5 and SEQ ID NO. 6.

Furthermore, the method for preparing the humanized RHO and/or RHO mutant mice is applied to the development of medicaments for treating RHO gene mutation related diseases.

The invention has the following beneficial effects: the invention adopts homologous recombination technology to replace the full length of the Rho gene of the mouse with the full length of the RHO gene of the human or the mutant gene thereof, realizes one-step targeting in ES cells, and the obtained mouse has reproductive transmission capability and short period; the mouse does not express the mouse Rho endogenous gene any more, and drives the transcription regulation of the human Rho full-length sequence under the endogenous regulation element of the mouse, so that various sequences in treatment evaluation can completely target the human Rho sequence, and the method has good application prospect in developing medicaments for treating diseases related to the Rho gene mutation.

Drawings

FIG. 1 is a PCR reaction system for PCR analysis and identification of the genomic DNA of ES cells obtained in example 2;

FIG. 2 shows the results of PCR analysis and identification (RHO) of the genomic DNA of ES cells obtained in example 2;

FIG. 3 shows the result of PCR analysis and identification (RHO-P23H) of the genomic DNA of ES cells obtained in example 2;

FIG. 4 is a diagram showing the identification of Southern blot of ES cells obtained in example 2;

FIG. 5 is a PCR reaction system for PCR analysis of rat tail genomic DNA of F0 mice obtained in example 3;

FIG. 6 shows the results of PCR analysis of rat tail genomic DNA of F0 mice obtained in example 3;

FIG. 7 shows the results of PCR analysis of the genomic DNA of the rat tail of Fn;

FIG. 8 is a diagram showing the phenotypic analysis of eyes in F1 mice of RHO-P23H and in Fn homozygous mice of RHO.

Detailed Description

The following description of the embodiments of the present invention will be made clearly and completely, and it is apparent that the described embodiments are only some embodiments of the present invention, but not all embodiments. All other embodiments, which can be made by those skilled in the art based on the embodiments of the invention without making any inventive effort, are intended to be within the scope of the invention.

The reagents or instruments used in the examples of the present invention were not manufacturer-identified and were conventional reagent products commercially available.

BAC: RP11-90I14 is derived from BACPAC Resources Center (BPRC)

Example 1

Vector construction

The 3-segment homologous recombination fragment upstream primer and the downstream primer matched with the same are designed, and related sequences are designed. The method comprises the following steps: PCR amplification is carried out by taking wild C57BL/6J mouse genome DNA as a template to obtain a 5 '-end homologous arm fragment and a 3' -end homologous arm fragment; PCR amplification is carried out by taking human BAC: RP11-90I14 as a template to obtain a human DNA fragment; neo resistance gene chip

5' homology arm (4125 bp): the mouse mm10 database is positioned as chr6:115,927,880-115,932,004 nucleotide (SEQ ID NO: 1), and the upstream primer (SEQ ID NO:25 '-agtgactgctgagccaaagttgg-3'); the downstream primer (SEQ ID NO: 35 '-ggctgcggctctcgaggctgcc-3'). Human DNA fragment (7136 bp): the human hg38 database is mapped to chr3:129,528,734-129,535,869 nucleotide (SEQ ID NO: 4): an upstream primer (SEQ ID NO: 55 '-atgaatggcacagaaggcccta-3') and a downstream primer (SEQ ID NO:6 5 '-catagtctcatctgctgcatgc-3'). 3' homology arm (4288 bp): the position of the mouse mm10 database is chr6:115,940,580-115,944,867 nucleotide (SEQ ID NO: 7); an upstream primer (SEQ ID NO:8 5 '-ccttacatgccgaggagtgatg-3') and a downstream primer (SEQ ID NO:9 5 '-ctgagcagccgaaagctgcc-3').

And connecting the 5 '-end homologous arm fragment, the 3' -end homologous arm fragment, the human DNA fragment and the Neo resistance gene fragment to the PUC57 plasmid through INFUION connection to finally obtain the targeting vector.

Example 2

ES cell electrotransformation

40ug of the targeting vector plasmid obtained in example I was extracted and electrotransferred into the ES cell line of the C57BL/6J strain, and after 24 hours of cell electrotransfer, the ES medium containing the drug for resistance was replaced. The ES cells were observed daily for 7 consecutive days, and fresh ES medium containing the drug for resistance was changed daily. On day 8, a well-conditioned, moderately large monoclonal pool was selected, and the clones were subjected to cell culture and subsequent genotyping and Southern identification.

Example 3

Taking blastocysts of albino C57BL/6 mice, injecting ES cells into the blastocysts, transplanting the blastocysts into oviducts of recipient mice, and producing genetically modified humanized mice to obtain the first-established mice (i.e. foundation mice, F0 generation) with C57BL/6J background. The obtained mice are crossed and selfed to expand population quantity, and stable mouse strains are established.

Example 4

Identification of genetically modified humanized cells and mice

1. ES cell genotyping and Southern identification

PCR analysis and identification were performed on the ES cell genomic DNA obtained in example 2 using three pairs of primers, respectively: the primer position F1 is positioned on the Neo element, R1 is positioned on the right side of the 3' homology arm, F2 is positioned on the 5' homology arm, R2 is positioned on the exon 1 of the human gene, F3 is positioned on the downstream of the 3' UTR of the human gene, and R3 is positioned on the Neo element.

F1(SEQ ID NO:10)：5’-GGCTGGTAAGGGATATTTGCCTG-3’

R1(SEQ ID NO:11)：5’-GGCTGGTAAGGGATATTTGCCTG-3’

F2(SEQ ID NO:12): 5’-TAGTATGATATCTCGCGGATGCTG-3’

R2(SEQ ID NO:13): 5’-GATCAGCAGAAACATGTAGGCG-3’

F3(SEQ ID NO:14): 5’-CCTAAGGGGATTAGATGCGACTG-3’

R3(SEQ ID NO:15): 5’-TCGACTGTGCCTTCTAGTTGC-3’

The PCR reaction system (20. Mu.L) is shown in FIG. 1.

The F1R1 primer product should be 4508bp in length, the F2R2 primer product should be 327bp in length, and the F3R3 primer product should be 406bp in length.

Of the 96 clones obtained, 24 clones were identified as positive clones, and the PCR identification results are shown in FIG. 2. Out of the 96 clones obtained, 35 clones among RHO-P23H were identified as positive clones, and the PCR identification results are shown in FIG. 3.

Further, 11 clones (RHO: 1C4, 1C6, 1D1, 1G5 and 1H7; RHO-P23H: 3A3, 3E1, 3F2, 3F3 and 3H 6) positive for PCR were confirmed by using the Southern blot method.

The genome is digested by BamHI enzyme, transferred to membrane and hybridized. Probes were located on the outside segments of the 5' homology arms, respectively. The probe synthesis primers are respectively as follows: P1-F (SEQ ID NO: 16), P1-R (SEQ ID NO: 17).

P1-F(SEQ ID NO:16)：5'-CTTAACAGGCAGAAGCAGGGAGATG-3'

P1-R(SEQ ID NO:17)：5'-CACGCGCTAATGGAAATCCTAACAC-3'

The successfully prepared genetically engineered cells are respectively generated by probe hybridization:

5' Probe 14.80. 14.80 kb-MT (with BamHI digestion). Whereas the wild type C56BL/6 mouse genome has only a 10.97kb band, no hybridization band is generated

The genome is digested by EcoRV enzyme, transferred to membrane and hybridized. Probes were located on the outside segments of the 3' homology arms, respectively. The probe synthesis primers are respectively as follows: P2-F (SEQ ID NO: 18), P2-R (SEQ ID NO: 19).

P2-F(SEQ ID NO:18)：5'-ATTTAAGTCACGCCGACAGGTTCTC-3'

P2-R(SEQ ID NO:19)：5'-GGCCATAAAGGACTGAGATTCGAGA-3'

The successfully prepared genetically engineered cells are respectively generated by probe hybridization:

3' Probe 9.39 kb-MT (with EcoRV digestion). Whereas the wild type C56BL/6 mouse genome has only a 12.24kb band, no hybridization band is generated

The experimental results showed that the size of the hybridization bands was consistent with the expected, confirming that 11 mice were positive clones and that random insertions were absent, numbered 1C4, 1C6, 1D1, 1G5 and 1H7, respectively, RHO-P23H: 3A3, 3E1, 3F2, 3F3 and 3H6. The Southern blot detection results are shown in FIG. 4.

2. Genotyping of F0 generation

PCR analysis was performed using two pairs of primers, respectively, on the rat tail genomic DNA of the F0 mice obtained in example 3, with the primer position F2 (SEQ ID NO: 12) on the 5 'homology arm, the R2 (SEQ ID NO: 13) on exon 1 of the human gene, the F1 (SEQ ID NO: 10) on the Neo element, and the R4 (SEQ ID NO: 20) on the 3' homology arm;

R4(SEQ ID NO:20)：5’-CCCTCTCCTCTGATAGTTGCAATAAA-3’

the PCR reaction system (20. Mu.L) is shown in FIG. 5.

The F2R2 primer product should be 545bp in length and the F1R4 primer product should be 536bp in length. The RHO is identified as positive mice in 5 mice in the obtained 5F 0 mice; RHO-P23H of the 8F 0 mice obtained, 8 mice were identified as positive mice. The PCR identification results are shown in FIG. 6.

3. Genotyping of F1 generation

Mice identified as positive for F0 were bred with wild-type mice to give F1-generation mice. PCR analysis was performed on F1 rat tail genomic DNA. The rat tail genomic DNA of the Fn mice was subjected to PCR analysis using the same primers identified for the F0 mice, respectively.

4. Fn generation genotyping

Mice identified as positive for F1 were mated to each other to give Fn-generation mice. PCR analysis was performed on the Fn-generation rat tail genomic DNA. PCR analysis was performed using three pairs of primers, respectively, on the rat tail genomic DNA of Fn-generation mice, with the primer position F5 (SEQ ID NO: 21) located at the endogenous Rho locus of the mice being replaced and the R5 (SEQ ID NO: 22) located on the 3' homology arm; f4 (SEQ ID NO: 23) at a locus downstream of the UTR of the humanized RHO gene; f6 (SEQ ID NO: 24) on the 5' homology arm and R6 (SEQ ID NO: 25) on the endogenous Rho locus of the mouse being replaced.

F5(SEQ ID NO:21)：5’-CCGAAGCAAATGACTTCCATCTG-3’

R5(SEQ ID NO:22)：5’-GTTCCCTCTCCTCTGATAGTTGC-3’

F4(SEQ ID NO:23): 5’-GGATTAGATGCGACTGTGGACTT-3’

F6(SEQ ID NO:24): 5’-CAAGCAGCCTTGGTCTCTGTCTAC-3’

R6(SEQ ID NO:25): 5’-TTGACAGGACAGGAGAAGGGAGAAG-3’

F5R5 was found to have a primer product length of 284 bp in wild-type mice, F4R5 primer product length of 559bp, whereas no band could be detected in wild-type mice, F6R6 primer product length of 536bp, whereas no band could be detected in wild-type mice. 3 mice in the obtained 5F 0-generation mice are identified as homozygous mice; the PCR identification results are shown in FIG. 7.

The F1-generation mice of RHO-P23H obtained in example 4 and Fn-generation homozygous mice of RHO were used for eye phenotyping.

After the mice were anesthetized, they were observed with a ophthalmoscope, and the experimental results showed that the RHO mouse phenotype was not different from that of the wild-type mice, whereas the RHO-P23H mouse eye phenotype was abnormal.

From the above examples, it can be understood that the invention adopts homologous recombination technology to replace the full length of the mouse Rho gene with the full length of the human Rho gene or the mutant gene thereof, and realizes one-step targeting in ES cells, and the obtained mouse has reproductive transmission capability and short period; the mouse does not express the mouse Rho endogenous gene any more, and drives the transcription regulation of the human Rho full-length sequence under the endogenous regulation element of the mouse, so that various sequences in treatment evaluation can completely target the human Rho sequence, and the method has good application prospect in developing medicaments for treating diseases related to the Rho gene mutation.

The foregoing has shown and described the basic principles, principal features and advantages of the invention. It will be appreciated by persons skilled in the art that the above embodiments are not intended to limit the invention in any way, and that all technical solutions obtained by means of equivalent substitutions or equivalent transformations fall within the scope of the invention.

Claims (10)

1. A method for preparing a humanized RHO and or a RHO mutant mouse, comprising replacing a mouse RHO nucleic acid sequence with a human RHO nucleic acid sequence or a mutant sequence thereof to form a modified RHO gene encoding a human or humanized RHO protein.

2. A method for preparing a humanized RHO and or RHO mutant mouse according to claim 1, wherein said RHO mutant is RHO-P23H.

3. A method for preparing a humanized RHO and or RHO mutant mouse according to claim 2, comprising the steps of: the mouse full-length RHO locus was replaced with 7.1kb human RHO genomic sequence and or with a 7.1kb fragment of the corresponding human RHO-P23H genomic DNA.

4. A method for preparing a humanized RHO and or RHO mutant mouse according to claim 3, wherein said mouse is a C57BL/6J mouse, said method comprising the steps of:

1) Constructing a targeting vector containing a human RHO or RHO-P23H sequence;

2) Transferring the targeting vector into mouse ES cells for homologous recombination to obtain positive ES cells;

3) Positive ES cell blastula injection to obtain F0 mice;

4) Identifying the genotype of the F0 mouse;

5) Producing F1 mice;

6) Producing F2 mice;

7) Phenotypic analysis of F2 mice.

5. The method for preparing humanized RHO and/or RHO mutant mice according to claim 4, wherein said targeting vector of step 1) comprises:

a 5 'homology arm sequence, a human RHO genomic sequence, an antibody screening element, and a 3' homology arm;

wherein the homologous arm sequence is amplified from the genome of a C57BL/6J mouse, and the human RHO genome sequence is cloned from BAC: RP11-90I 14.

6. A method for preparing a humanized RHO and or RHO mutant mouse according to claim 5, wherein said homologous recombination of step 2) comprises the steps of:

and (3) electrically transferring the constructed targeting vector into ES cells of a C57BL/6J strain, screening the ES clones with drug resistance through drug screening, culturing and amplifying the related ES clones, and then carrying out PCR typing identification and Southern identification to obtain positive ES cells with correct targeting.

7. A method for preparing a humanized RHO and or RHO mutant mouse according to claim 6, wherein said method of preparing comprises the steps of:

(1) Constructing a targeting vector, wherein the targeting vector comprises a 5 'homology arm sequence, a human RHO genome sequence, an antibody screening element and a 3' homology arm, wherein the homology arm sequence is obtained by amplifying a genome of a C57BL/6J mouse, and the human RHO genome sequence is obtained by cloning BAC: RP11-90I 14;

(2) Electrotransferring the constructed plasmid into ES cells of a C57BL/6J strain, screening medicines, selecting the ES clone with medicine resistance, culturing and amplifying the related ES clone, and carrying out PCR typing identification and Southern identification to obtain positive ES cells with correct targeting;

(3) Injecting positive ES cells into blastula, transplanting blastula into a surrogate mice, and birth of the mice after about 20 days of gestation;

(4) Shearing young mouse paws of 5-7d, extracting DNA, and carrying out PCR typing identification to confirm the genotype of the mouse;

(5) After male foundation mice are mated with wild-type heterologous mice for 8 weeks of age to obtain F1 generation heterozygote mice, carrying out PCR identification on the mice after 7 days of birth, and if positive mice are born, indicating that transgenes are integrated into germ cells;

(6) After male F1 mice reach 8 weeks of age, female F1 mice reach 6 weeks of age, carrying out mutual hybridization, and carrying out PCR identification after F2 mice are born for 7 days, and confirming the birth of homozygote mice;

(7) Phenotype analysis is carried out on RHO homozygote mice and RHO-P23H heterozygote mice, and other characteristics such as retina morphology, structure and the like are analyzed.

8. A method for preparing a humanized RHO and/or RHO mutant mouse according to claim 7,

the 5' homologous arm sequence is shown as SEQ ID NO. 1;

the 3' homologous arm sequence is shown as SEQ ID NO. 7;

the human RHO genome sequence is shown as SEQ ID NO. 4.

9. A method for preparing a humanized RHO and/or RHO mutant mouse according to claim 8,

the upstream and downstream primer sequences for obtaining the 5' homologous arm sequences are respectively shown as SEQ ID NO. 2 and SEQ ID NO. 3;

the upstream and downstream primer sequences for obtaining the 3' homologous arm sequences are respectively shown as SEQ ID NO. 8 and SEQ ID NO. 9;

the sequences of the upstream and downstream primers for obtaining the human RHO genome sequence are respectively shown as SEQ ID NO. 5 and SEQ ID NO. 6.

10. Use of the method of any one of claims 1-9 in the manufacture of a medicament for the treatment of a disease associated with a mutation in the RHO gene.